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Abstract
Hyperhomocysteinaemia has been identified as a risk factor for 
cerebrovascular, peripheral vascular, and coronary heart dis-
ease.1-4 Elevated levels of plasma homocysteine can result from 
genetic or nutrient-related disturbances in the trans-sulphuration 
or re-methylation pathways for homocysteine metabolism.1,5–7 
5,10-Methylenetetrahydrofolate reductase (MTHFR) catalyzes 
the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetra-
hydrofolate, the predominant circulatory form of folate and carbon 
donor for the re-methylation of homocysteine to methionine. Re-
duced MTHFR activity with a thermolabile enzyme has been re-
ported in patients with coronary and peripheral artery diseases.6 
We have identified a common mutation in MTHFR which alters 
a highly-conserved amino acid; the substitution occurs at a fre-
quency of approximately 38% of unselected chromosomes. The 
mutation in the heterozygous or homozygous state correlates with 
reduced enzyme activity and increased thermolability in lympho-
cyte extracts; in vitro expression of a mutagenized cDNA contain-
ing the mutation confirms its effect on thermolability of MTHFR. Fi-
nally, individuals homozygous for the mutation have significantly 
elevated plasma homocysteine levels. This mutation in MTHFR 
may represent an important genetic risk factor in vascular disease. 
Severe MTHFR deficiency, the most common inborn error 
of folate metabolism, results in hyperhomocysteinaemia, ho-
mocystinuria, and hypomethioninaemia. Patients with severe 
MTHFR deficiency (0-20% residual activity in cultured fibro-
blasts) present in infancy or adolescence with developmental 
delay, motor and gait dysfunction, seizures, psychiatric distur-
bances, and other neurological abnormalities; they are also at 
risk for vascular complications.8 Individuals with 50% resid-
ual activity, due to a thermolabile form of the reductase, were 
first reported in approximately 17% of 212 North American 
patients with coronary artery disease.5 A recent study of the 
Netherlands population identified the thermolabile variant in 
different forms of premature vascular disease,6 and estimated 
its incidence to be 7% of vascular patients. The presence of a 
thermolabile MTHFR is predictive of coronary artery stenosis, 
independent of other risk factors, such as age, smoking, hyper-
cholesterolaemia, and hypertension.9 
Our recent isolation of a cDNA for human MTHFR10 has 
enabled us to identify nine mutations in this gene, in the se-
verely-deficient group of patients, by SSCP analysis and direct 
sequencing of PCR fragments.10,11 Using the same procedures, 
we identified a C to T substitution at nucleotide (nt) 677, which 
converts an alanine to a valine residue (Figure 1a). This altera-
tion creates a HinfI site (Figure 1b), which was used to screen 
114 unselected French Canadian chromosomes; the allele fre-
quency of the substitution was 0.38. The frequency of the three 
genotypes were as follows: –/–, 37%; +/–, 51%; and +/+, 12% 
(+ indicates the presence of the HinfI site and a valine residue). 
As these individuals were not examined clinically or biochem-
ically, they cannot be considered as a control group. 
We next performed genotypic analysis and measured en-
zyme activity and thermolability in a total of 40 lymphocyte 
pellets from patients with premature vascular disease and 
controls (Table I). We selected 13 vascular patients from our 
previous study, among whom five were considered to have 
thermolabile MTHFR.6 From a large reference group of 89 
controls, we studied all seven individuals who had thermo-
labile MTHFR, and selected at random an additional 20 con-
trols with normal MTHFR from the same reference group. 
The mean MTHFR activity for individuals homozygous for 
the Ala to Val substitution (+/+) was approximately 30% of 
the mean activity for (–/–) individuals. Heterozygotes had a 
mean MTHFR activity of 65% compared to (–/–) individuals, 
intermediate between values for (–/–) and (+/+) individuals. 
The ranges of activities showed some overlap for the hetero-
zygous and (–/–) genotypes, but homozygous (+/+) individ-
uals showed virtually no overlap with the other two groups. 
A one-way analysis of variance yielded a P value <.0001; 
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Figure 1. Sequence change and restriction enzyme analysis for the al-
anine to valine substitution. a) Sequence of two individuals, a homo-
zygote for the alanine residue and a homozygote for the valine resi-
due. The antisense strands are depicted. The primers for analysis of 
the A→V change are: 5’-TGAAGGAGAA GGTGTCTGCG GGA-3’ (ex-
onic) and 5’-AGGACGGTGC GGTGAGAGTG-3’ (intronic); these prim-
ers generate a fragment of 198 bp. b) The substitution creates a HinfI 
recognition sequence which digests the 198 bp fragment into 175 and 
23 bp fragments; the latter fragment has been run off the gel. All three 
possible genotypes are shown.  
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a pairwise Bonferroni t test showed that all three genotypes 
were significantly different with P < 0.01 for the three possi-
ble combinations. 
The three genotypes were all significantly different (P < .01) 
with respect to enzyme thermolability. The mean residual ac-
tivity after heat inactivation (5 min at 46°C) was 67% (–/–), 
56% (+/–) and 22% (+/+). While the degree of thermolability 
overlaps somewhat for (–/–) individuals and heterozygotes, 
individuals with two mutant alleles had a distinctly lower 
range. Every individual with the (+/+) genotype had residual 
activity <35% after heating, and specific activity <50% of that 
of the (–/–) genotype. 
Fasting homocysteine levels in (+/+) individuals were al-
most twice the value for (+/–) and (–/–) individuals. The dif-
ferences among genotypes for plasma homocysteine were 
maintained when homocysteine was measured following six 
hours of methionine loading. A one-way anova yielded a P < 
.01 for the fasting and post-methionine homocysteine levels. 
A pairwise Bonferroni t test showed that homozygous mutant 
individuals had significantly elevated homocysteine levels (P 
< .05),compared to either (+/–) or (–/–) individuals. 
We have used the original MTHFR cDNA (1.3 kb) to isolate 
a 2.2 kb cDNA, which contained an additional 900 bp at the 3’ 
end; the latter contained a termination codon, 100 bp of 3’ UTR 
and a poly A tail (GenBank# UO9806). The open reading frame 
of 1980 bp predicts a protein of 74.6 kDa. The purified porcine 
liver enzyme has been shown to have subunits of 77 kDa.12 
Western analysis (Figure 2a) of several human tissues and of 
porcine liver reveals a polypeptide of 77 kDa, as well as an ad-
ditional polypeptide of approximately 70 kDa in human fetal 
liver and in porcine liver, suggesting the presence of isozymes. 
The wild-type cDNA and a mutagenized cDNA, containing 
the Ala to Val substitution, were expressed in E. coli to yield 
a protein of approximately 70 kDa (Figure 2a), which co-mi-
grates with the smaller polypeptide mentioned above. Treat-
ment of extracts at 46°C for five minutes revealed that the 
enzyme containing the substitution was significantly more 
thermolabile than the wild -type enzyme (P < .001; Figure 2b). 
The expression experiments were not designed to measure 
differences in specific activity before heating, since variation 
in efficiencies of expression could contribute to difficulties in 
interpretation. Curiously though, the specific activity for the 
mutant construct was higher in both experiments. It is possi-
ble that the mutant protein has increased stability in E. coli, or 
that inclusion bodies in our extracts contributed to differences 
in recovery of properly-assembled enzyme. 
The alanine residue is conserved in porcine MTHFR and 
in the corresponding bacterial metF genes.10 We have also ob-
served a region of homology in the human dihydrofolate re-
ductase (DHFR) gene,11 although the alanine residue itself is 
not conserved; this region of amino acids 130-149 of DHFR 
contains Thr136, which has been implicated in folate binding 
of human DHFR.13 This region in MTHFR might also be in-
volved in folate binding, and the enzyme may be stabilized in 
the presence of folate. This hypothesis is compatible with the 
well-documented influence of folate on homocysteine levels7,14 
and with the reported correction of mild hyperhomocysteinae-
mia by folic acid in individuals with premature vascular dis-
ease14 and thermolabile MTHFR.15 
Table 1. Correlation between MTHFR genotype and enzyme activity, 
thermolability, and plasma homocysteine level 
  Genotype 
 –/–    +/–    +/+
 n=19  n=9  n=12 
Specific activitya,b  22.9±1.7  15.0±0.8  6.9±0.6 
(nmol CH2O/mg protein/hr)  (11.8–33.8)  (10.2–18.8)  (2.6–10.2) 
Residual activity  66.8±1.5  56.2±2.8  21.8±2.8 
after heatingsa,b (%)  (55–76)  (41–67)  (10–35) 
Plasma homocysteinea,c  12.6±1.1  13.8±1.0  22.4±2.9 
(μM)(after fasting)  (7–21)  (9.6–20)  (9.6–42) 
Plasma homocysteinea,c  41.3±5.0d  41±2.8  72.6±11.7e
(μM)(post-methionine load)  (20.9-110)  (29.1-54)  (24.4-159) 
Enzyme activity and plasma homocysteine were determined as pre-
viously reported.6 Each value represents mean ± standard error. The 
range is given in parentheses below the mean. a. one-way anova P < 
.01. b. paired t test for all combinations P < .01. c. paired t test P < .05 
for +/+ group versus +/– group or –/– group; P > .05 for +/– versus –/– 
group. d. n = 18. e. n = 11.  
Figure 2. Expression analysis of MTHFR in E. coli. a) Western blot of bacterial extracts and tissues. Two μg of bacterial extract protein was used 
for lanes 1-3. The tissues (lanes 4-6) were prepared by homogenization in 0.25 M sucrose with aprotinin and leupeptin, followed by sonication 
on ice. The extracts were spun for 15 min in a microcentrifuge at 14,000g and 100 μg of supernatant protein was used for western analysis. h, 
human; p, porcine. b) Thermolability assay of bacterial extracts. Two separate experiments (with 3-4 replicates construct experiment) were per-
formed to measure thermostable activity of the wild-type and mutagenized MTHFR cDNAs. The values shown represent mean ± standard error for 
each experiment, as % of residual activity after heating. The means of the specific activities before heating (expressed as nmol formaldehyde/hr/
mg protein) were as follows: 3.8 and 5.3 (Exp. 1) and 6.2 and 7.5 (Exp. 2) for MTHFR and MTHFR A→V, respectively.  
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Our data have identified a common genetic change in 
MTHFR which results in thermolability; our experiments do 
not directly address the relationship between this change and 
vascular disease. Nonetheless, this mutation represents a di-
agnostic test for evaluation of MTHFR thermolability in hy-
perhomocysteinaemia. Large case-control studies are required 
to evaluate the frequency of this genetic change in various 
forms of occlusive arterial disease and to examine the interac-
tion between this genetic marker and dietary factors, such as 
folate intake. Well-defined populations need to be examined, 
as the limited data set thus far suggests that population-spe-
cific allele frequencies may exist. More importantly, however, 
the identification of a candidate genetic risk factor for vascu-
lar disease, which may be influenced by nutrient intake, rep-
resents a critical step in the design of appropriate therapies for 
the homocysteinaemic form of arteriosclerosis. 
Methodology 
Mutation identification. Primers were designed from the cDNA se-
quence to generate 250-300 bp fragments which overlapped 50-75 bp 
at each end. When PCR amplification of human genomic DNA yielded 
larger fragments than expected for the coding region alone, these frag-
ments were presumed to contain introns and were sequenced directly 
(Cycle Sequencing kit, GIBCO). Intronic primer sequences were ob-
tained with this strategy. PCR products were analyzed by a non-ra-
dioactive SSCP protocol as described.10 Fragments showing a shift 
on SSCP gels were subcloned into Bluescript and sequenced (Seque-
nase kit, USB). To confirm the sequence changes, a new PCR was per-
formed with genomic DNA; the PCR product was digested with HinfI 
and analyzed by polycrylamide gel electrophoresis. 
Clinical material. To determine the frequency of the A→V mutation, 
DNA from 57 individuals from Quebec was analyzed by PCR and re-
striction digestion. The individuals, all French Canadian, were not ex-
amined clinically or biochemically. The 40 individuals analyzed in Ta-
ble 1 have been described.6 Of the 13 cardiovascular patients, eight 
had cerebrovascular arteriosclerosis, and five had peripheral arterio-
sclerosis. Five had thermolabile MTHFR, while eight had thermosta-
ble MTHFR (>33% residual activity after heating). Controls and patients 
were all Dutch-Caucasian, between 20–60 years of age. None of these in-
dividuals used vitamins that could alter homocysteine levels. Enzyme 
assays and homocysteine determinations have also been reported.6 
Constructs for expression analysis. A human colon carcinoma cDNA 
library (gift of Nicole Beauchemin, McGill University) was screened by 
plaque hybridization with the original 1.3 kb cDNA10 to obtain addi-
tional coding sequences. A cDNA of 2.2 kb was isolated, which contained 
900 additional bp at the 3’ end (Genbank accession number UO9806). Se-
quencing was performed on both strands for the entire cDNA. Addi-
tional 5’ sequences (800 bp) were obtained from a human kidney cDNA 
library (Clontech), but these sequences did not contain additional coding 
sequences and were therefore used for the PCR-based mutagenesis only 
(see below) and not for the expression analysis. The two cDNAs (2.2 kb 
and 800 bp) were ligated using the EcoRI site at nt 199 and inserted into 
Bluescript (Stratagene). The 2.2 kb cDNA was subcloned into the expres-
sion vector pTrc99A (Pharmacia) using the NcoI site at nt 11 and the XbaI 
site in the polylinker region of both vectors. Sequencing was performed 
across the cloning sites to verify the wild-type construct. 
PCR-based mutagenesis, using the cDNA-containing Bluescript 
vector as template, was used to create the A to V mutation identified.16 
Vent polymerase (NEB) was used to reduce PCR errors. The following 
primers were used: primer 1, bp -200 to -178, sense; primer 2, bp 667 
to 687, antisense, containing a mismatch, A, at nt 677; primer 3, 667 to 
687, sense, containing a mismatch, T, at nt 677; primer 4, bp 1092 to 
1114, antisense. PCR was performed using primers 1 and 2 to generate 
a product of 887 bp, and using primers 3 and 4 to generate a product 
of 447 bp. The two PCR fragments were isolated from a 1.2% agarose 
gel by Geneclean (BIO 101). A final PCR reaction, using primers 1 and 
4 and the first two PCR fragments as template, was performed to gen-
erate a 1.3 kb band containing the mutation. The 1.3 kb fragment was 
digested with NcoI and MscI, and inserted into the wild-type cDNA-
containing expression vector by replacing the sequences between the 
NcoI site at bp 11 and the MscI site at bp 943. The entire replacement 
fragment and the cloning sites were sequenced to verify that no addi-
tional changes were introduced by PCR. 
Expression analysis. Overnight cultures of JM 105 containing vector, 
wild-type, or mutagenized MTHFR cDNA were grown at 37 °C in 2 
× YT media with .05 mg ml–1 ampicillin. Fresh 10 ml cultures of each 
were inoculated with approximately 50 μl of overnight cultures and 
grown at 37 °C to an O.D. of 1 at 420 nM. Cultures were then induced 
for 2 h with 1 mM IPTG and pelleted. The cells were resuspended in 
TE buffer with 2 μg ml–1 aprotinin and leupeptin (3.5 × wet weight 
of cells). Cell suspensions were sonicated on ice for 3 × 15 s and cen-
trifuged for 30 min at 4 °C to pellet cell debris and unlysed cells. The 
supernatant was removed and assayed for protein concentration with 
the Bio-Rad protein assay. Western analysis was performed using the 
Amersham ECL kit with antiserum generated against purified porcine 
liver MTHFR.12 Enzymatic assays were performed by established pro-
cedures.17 Thermolability was assessed by pre-treating the extracts at 
46 °C for 5 min before determining activity. Specific activities (nmol 
formaldehyde/h/mg protein) were calculated for the 2 cDNA-con-
taining constructs after subtraction of the values obtained with vector 
alone (to subtract background E. coli MTHFR activity). 
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